Peptides
Abaloparatide: bone-building evidence and the catalog-vial gap
Abaloparatide is a bone-building medicine, not a general recovery or muscle-growth peptide. The approved U.S. product, Tymlos, treats postmenopausal women with osteoporosis at high fracture risk and increases bone density in men with osteoporosis at high fracture risk. Its evidence and labeling concern a manufactured, regulated prefilled pen. A supplier's 3 mg research vial has not been shown to be equivalent. [1]
How does it work?
Abaloparatide activates the parathyroid hormone type 1 receptor. Intermittent exposure can stimulate new bone formation. The outcome that matters is whether people have fewer fractures, not simply whether a bone marker changes. [1,2]
What do human studies show?
In the 18-month ACTIVE randomized trial, 2,463 postmenopausal women with osteoporosis were assigned to abaloparatide, placebo, or an active comparator. New vertebral fractures were observed in 0.58% of evaluable abaloparatide participants and 4.22% of placebo participants. That is a substantial result for this studied population and formulation; the trial does not test healthy adults, athletes, or a research vial. [2]
The U.S. label supports a narrower claim for men: increasing bone density in men with osteoporosis at high fracture risk. It should not be read as proof of fracture reduction in men or of a general bone-recovery benefit. [1]
What are the main safety limits?
The current label warns about severe allergic reactions, dizziness or low blood pressure shortly after dosing, high blood or urine calcium, and possible kidney-stone concerns. Bone tumors occurred in rats at higher exposures; whether the medicine causes osteosarcoma in humans is unknown. The label advises avoiding it in people with factors that raise osteosarcoma risk and does not recommend more than two years of lifetime treatment. Those decisions belong with an osteoporosis clinician who can assess fracture risk, other illnesses, and monitoring. [1]
PRESCRIPTION-LABEL CONTEXT
How much?
SOURCE CONTEXT
What it refers to
approved prescription dose of Tymlos by subcutaneous injection once daily for its labeled osteoporosis uses.
80 mcg — approved prescription dose of Tymlos by subcutaneous injection once daily for its labeled osteoporosis uses. The prefilled pen delivers this fixed dose; the current label does not recommend more than two years of treatment during a patient's lifetime. [1]
Read detailed dosing notes
This is not an anecdotal fitness dose or a mixing instruction for the 3 mg catalog vial. The vial's identity, sterility, formulation, and dose delivery have not been established as equivalent to Tymlos, so no dose can responsibly be transferred from the prescription pen to that product. [1]